Canada Supports Leqembi for Alzheimer's Patient Reimbursement
Here comes a curveball from the great white north! Canada’s Drug Agency has thrown its weight behind BioArctic and Eisai's Leqembi, recommending public reimbursement for those battling mild cognitive impairment or mild dementia due to Alzheimer's. This is more than just another tick on a list—it's a potential gamechanger for patients. What's the Big Deal? The...
Continue Reading